Nature Microbiology | Dietary Zinc Deficiency Promotes Acinetobacter baumannii Lung Infection via IL-13

This study reveals how dietary zinc deficiency promotes Acinetobacter baumannii lung infection through IL-13, providing a potential target for the treatment of pneumonia in high-risk populations.

Literature Overview
This article, titled 'Dietary zinc deficiency promotes Acinetobacter baumannii lung infection via IL-13 in mice', was published in 'Nature Microbiology'. It reviews and summarizes the impact of dietary zinc deficiency on Acinetobacter baumannii lung infection and its immune mechanisms. The study highlights the role of IL-13 in promoting pathogen dissemination and increasing mouse mortality, while finding that anti-IL-13 treatment can effectively reduce this dissemination risk.

Background Knowledge
Acinetobacter baumannii is a multidrug-resistant pathogen and a major causative agent of ventilator-associated pneumonia, particularly prevalent among the elderly, hospitalized patients, and immunocompromised individuals. Zinc is an essential nutrient for maintaining normal immune function, and zinc deficiency is associated with increased susceptibility to pneumonia. Although previous studies have shown that zinc supplements can enhance immunity and reduce pneumonia incidence, it remains unclear whether zinc deficiency directly promotes Acinetobacter baumannii infection and its specific mechanisms. This study uses a mouse model to systematically evaluate the impact of dietary zinc levels on Acinetobacter baumannii lung infection and reveals the potential of IL-13 as a therapeutic target, offering new directions for clinical interventions.

Research Methods and Experiments
The research team employed a C57BL/6J mouse model, controlling dietary zinc levels (low zinc vs. control group) to assess their impact on Acinetobacter baumannii lung infection. After infection, cytokines, pathogen burden, and host immune responses were analyzed using flow cytometry, histological analysis, ELISA, and competitive infection assays.

Key Conclusions and Perspectives

• Dietary zinc deficiency significantly increases the pathogen burden of Acinetobacter baumannii in the lungs, promoting its dissemination to the spleen and systemic tissues, which correlates with increased mouse mortality.
• Zinc-deficient mice produce elevated levels of pro-inflammatory cytokines, particularly IL-13, whose levels significantly increase after 24 hours post-infection.
• Neutralizing antibodies against IL-13 effectively reduce the dissemination and mortality of Acinetobacter baumannii in zinc-deficient mice.
• In zinc-sufficient mice, exogenous IL-13 promotes the dissemination of Acinetobacter baumannii but is insufficient to increase mortality independently.
• Dietary zinc status, rather than bacterial zinc status, is a critical determinant of susceptibility to Acinetobacter baumannii lung infection.
• No significant defects in lung barrier function or innate immune responses were observed in zinc-deficient mice, but significant increases in serum lactate dehydrogenase (LDH), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels suggest that cardiac and hepatic damage might contribute to increased mortality.

Conclusion
This study establishes a causal relationship between dietary zinc deficiency and Acinetobacter baumannii lung infection, revealing the critical role of IL-13 in pathogen dissemination. Dietary zinc deficiency not only impairs immune function but may also promote pathogen spread by altering the cytokine environment. Anti-IL-13 antibody treatment demonstrates protective effects in zinc-deficient mice, suggesting therapeutic potential for high-risk clinical populations. These findings provide new targets for pneumonia treatment and emphasize the importance of nutritional status in infection susceptibility. Future research should further validate the role of these mechanisms in other pathogens and explore the feasibility of combining zinc supplementation with anti-IL-13 therapy.

ImmuneBuilder（AntiBody）

View Tool Details

ImmuneBuilder, including ABodyBuilder2, NanoBodyBuilder2, and TCRBuilder2, is specifically designed for predicting the structure of immunoproteins (e.g., antibodies, nanobodies, and T-cell receptors), and employs AlphaFold-Multimer's structural modules with modifications specific to the immunoproteins to improve prediction accuracy.ImmuneBuilder is able to quickly generate immunoprotein structures that resemble experimental data much faster than AlphaFold2 and without the need for large sequence databases or multiple sequence comparisons. The tool's features include high accuracy, fast prediction, and open-source accessibility for structural analysis of large-scale sequence datasets, especially in the study of immunoprotein structures from next-generation sequencing data. immuneBuilder also provides error estimation to help filter out erroneous models, enhancing its value for applications in biotherapeutics and immunology research. Figure 1 shows the architecture of AbBuilder2, and the same architecture is used for NanoBodyBuilder2 and TCRBuilder2.